These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 25109330)

  • 1. Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma.
    Roesch A
    Oncogene; 2015 Jun; 34(23):2951-7. PubMed ID: 25109330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma.
    Roesch A; Paschen A; Landsberg J; Helfrich I; Becker JC; Schadendorf D
    Eur J Cancer; 2016 May; 59():109-112. PubMed ID: 27023049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting MAPK pathway in melanoma therapy.
    Cheng Y; Zhang G; Li G
    Cancer Metastasis Rev; 2013 Dec; 32(3-4):567-84. PubMed ID: 23584575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].
    Capovilla M
    Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF, a target in melanoma: implications for solid tumor drug development.
    Flaherty KT; McArthur G
    Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors.
    Delmas A; Cherier J; Pohorecka M; Medale-Giamarchi C; Meyer N; Casanova A; Sordet O; Lamant L; Savina A; Pradines A; Favre G
    Oncotarget; 2015 Jun; 6(17):15250-64. PubMed ID: 26098773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
    Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A
    J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
    Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
    Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapy resistance mechanisms and therapeutic implications in melanoma.
    Chen G; Davies MA
    Hematol Oncol Clin North Am; 2014 Jun; 28(3):523-36. PubMed ID: 24880945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma.
    Carlino MS; Long GV; Kefford RF; Rizos H
    Crit Rev Oncol Hematol; 2015 Dec; 96(3):385-98. PubMed ID: 26358420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
    Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA
    Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting BRAF in melanoma: biological and clinical challenges.
    Mandalà M; Voit C
    Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
    Wang AX; Qi XY
    IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomics approaches to understanding mitogen-activated protein kinase inhibitor resistance in melanoma.
    Paulitschke V; Eichhoff O; Cheng PF; Levesque MP; Höller C
    Curr Opin Oncol; 2016 Mar; 28(2):172-9. PubMed ID: 26742019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
    Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular targeted therapy for patients with melanoma: the promise of MAPK pathway inhibition and beyond.
    Sullivan RJ; Atkins MB
    Expert Opin Investig Drugs; 2010 Oct; 19(10):1205-16. PubMed ID: 20687784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to BRAF-targeted therapy in melanoma.
    Sullivan RJ; Flaherty KT
    Eur J Cancer; 2013 Apr; 49(6):1297-304. PubMed ID: 23290787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trametinib (GSK1120212) in the treatment of melanoma.
    Salama AK; Kim KB
    Expert Opin Pharmacother; 2013 Apr; 14(5):619-27. PubMed ID: 23432625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma.
    Andrews MC; Turner N; Boyd J; Roberts AW; Grigg AP; Behren A; Cebon J
    Clin Cancer Res; 2015 Dec; 21(23):5222-34. PubMed ID: 26202951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond Genomics: Multidimensional Analysis of Cancer Therapy Resistance.
    Philip M; Schietinger A
    Trends Immunol; 2015 Nov; 36(11):665-667. PubMed ID: 26440701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.